According to Report, the global Cell Therapy market size is expected to be worth around US$ 45 billion by 2030. The global Cell Therapy market size was valued at US$ 15 billion in 2021 and is anticipated to grow at a CAGR of 14.9% during forecast period 2022 to 2030.
According to Report, the global Cell Therapy market size is expected to be worth around US$ 45 billion by 2030. The global Cell Therapy market size was valued at US$ 15 billion in 2021 and is anticipated to grow at a CAGR of 14.9% during forecast period 2022 to 2030.
Key Takeaway
- The research-use segment accounted largest revenue share of around 62% in 2021
- The clinical-use segment is expected to grow at a gradual rate of 13.6% from 2022 to 2030
- By therapy type, the autologous therapies segment accounted for the largest revenue share of 54% in 2021
- North America is estimated to hold the largest market share of 53% in 2021
- In Asia Pacific is expected to grow at a CAGR of 15.65% over the forecast period 2022 to 2030
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/37509
Cell therapy is a technology that relies on replacing diseased or dysfunctional cells with healthy functioning ones. Cells mainly used for such advanced therapies are stem cells, owingtotheir ability to differentiate into specific cells required for repairing damaged or defective tissues or cells. Moreover, cell therapy finds its application in development of regenerative medicines, which is a multidisciplinary area aimed at maintenance, improvement, or restoration of cell, tissue, or organ function using methods mainly related to cell therapy. In addition, cells such as blood and bone marrow cells, mature, immature & solid tissue cells, adult stem cells, and embryonic stem cellsare widely used in cell therapy procedures. Moreover, transplanted cells including induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), neural stem cells (NSCs), and mesenchymal stem cells (MSCs) are divided broadly into two main groups including autologous cell therapy and non-autologous cell therapy.
Cell therapy is a technology that relies on replacing diseased or dysfunctional cells with healthy functioning ones. Cells mainly used for such advanced therapies are stem cells, owing to their ability to differentiate into specific cells required for repairing damaged or defective tissues or cells. Moreover, cell therapy finds its application in development of regenerative medicines, which is a multidisciplinary area aimed at maintenance, improvement, or restoration of cell, tissue, or organ function using methods mainly related to cell therapy. In addition, cells such as blood and bone marrow cells, mature, immature & solid tissue cells, adult stem cells, and embryonic stem cellsare widely used in cell therapy procedures. Moreover, transplanted cells including induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), neural stem cells (NSCs), and mesenchymal stem cells (MSCs) are divided broadly into two main groups including autologous cell therapy and non-autologous cell therapy.
Scope of the Report
| Report Coverage | Details |
| Market Size in 2021 | USD 15 Billion |
| Revenue Forecast by 2030 | USD 45 Billion |
| CAGR | 14.9% from 2022 to 2030 |
| Largest Market | North America |
| Fastest Growing Region | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
Growth Factors
The emergence of new technologies to support the development of advanced cellular therapies has aided in market growth. Companies are leveraging new technologies not only for the expansion of their product portfolio but also for establishing out-licensing or co-development agreements with other entities to support their product development programs.
Cell-based therapies hold great potential for replacing, repairing, restoring, or regenerating damaged tissues, and organs. Researchers are making huge investments in the development of such effective and safe treatments as an alternative to conventional treatment strategies which can be further attributed to the market growth. Out of all therapeutic areas, oncology has the highest number of ongoing T cells, CD34+ and/or CD133+ stem cells, mesenchymal stem/stromal cells are predominantly employed for clinical investigation.
The majority of biopharmaceutical entities have been affected by the COVID-19 pandemic, while several cellular therapy development companies have witnessed a strongly negative impact, which can be attributed to complications in logistics as well as the manufacturing models employed in this industry. In addition, substantial and stable funding is imperative to ensure successful commercial translation of cell-based therapeutics, a factor that was negatively affected in 2020, further affecting the market growth.
Furthermore, increase in financing and investments to support launch of new companies is expected to boost organic revenue growth ofthe market. For instance, in July 2019, Bayer invested $215 million for launch of Century Therapeutics, a U.S.-based biotechnology startup that aimed at developing therapies for solid tumors and blood cancer. Funding was further increased to $250 billion by a $35 million contribution from Versant Ventures and Fujifilm Cellular Dynamics, which is anticipated to further boost the market growth.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37509
Use-type Insights
The research-use segment dominated the market for cell therapy and accounted for the largest revenue share of 62% in 2021. The stem cells are majorly being used for research projects, which in turn, has led to a large revenue share for the research-use segment. The region is expected to continue its dominance from 2022 to 2030. Cell-based therapies hold great potential for replacing, repairing, restoring, or regenerating damaged tissues, cells, and organs. Researchers are making huge investments in the development of such effective and safe treatments as an alternative to conventional treatment strategies.
Mesenchymal Stem Cells (MSCs) have the potential to address several clinical implications, including moderation of the immune system. Thus, the interest of professionals in employing MSC-based therapy in the management of COVID-19 has spiked in 2020. This can be attributed to the fact that MSCs lack Angiotensin-converting Enzyme-2 (ACE2) receptor. This receptor observes a wide distribution over the human cell surface and is required by coronaviruses for entry into host cells. This property ensures that MSCs, if injected into host cells, have the ability to attain immunomodulatory effects without being affected by the coronavirus.
The clinical-use segment is expected to grow at a gradual rate of 13.4% through the forecast period owing to the less penetration of this segment. However, few cell therapies are approved for clinical applications such as CARTISTEM, Invossa, MACI, Epicel, Cellgram-AMI, Cupistem, Cellistem IC, GINTUIT, Prochymal, and Imlygic, and which is anticipated to encourage the companies to invest in this segment.
Therapy Type Insights
The autologous therapies segment dominated the cell therapy market and accounted for the largest revenue share of 54% in 2021. The segment is expected to maintain its dominance during the forecast period. This can be attributed to several advantages associated with autologous transplants such as easy availability, no need to identify an HLA-matched donor, lower risk of life-threatening complications, no risk of GVHD, and no necessity of immunosuppressive therapy. In addition, autologous therapies are affordable when compared to allogenic therapies which can be further attributed to segment growth.
The allogenic therapies segment is expected to witness comparatively slow growth through 2021 to 2028 owing to the high cost associated with allogenic transplants and relatively lower relapse rates. However, growth in cell banking and companies’ shift towards the development of allogenic therapy products is driving the market for cell therapy.
Regional Insights
North America is estimated to hold the largest market share of 53% in 2021. The large share of the region can be attributed to the presence of a substantial number of centers and institutes that are engaged in R&D pertaining to stem cell therapy. Out of the 8such leading universities throughout the world, 5 are U.S.-based institutes, including Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Harvard Stem Cell Institute, Harvard University, and Yale Stem Cell Center.
In Asia Pacific, the market for cell therapy is anticipated to witness a lucrative growth rate of 15.52% over the forecast period. The rising investment by the developers and consumers in educating themselves for advanced medicinal therapies is anticipated to boost the revenue generated from the developing economies of this region. There are several stem cell consortiums in Asian countries, which aim at ensuring ordinated and focused R&D programs. Moreover, patients from western countries are observed to migrate to Asian countries for treatment, owing to the flexible legal framework.
Key Players
- KolonTissueGene, Inc.
- Anterogen Co., Ltd.
- JCR Pharmaceuticals Co., Ltd.
- Castle Creek Biosciences, Inc.
- The Future of Biotechnology, MEDIPOST
- Osiris Therapeutics, Inc.
- PHARMICELL Co., Ltd
- Tameika Cell Technologies, Inc.
- Cells for Cells
- NuVasive, Inc.
- Vericel Corporation
- Celgene Corporation
Market Segmentation
- Use-type Outlook
- Clinical-use
- By Therapeutic Area
- Malignancies
- Muscoskeletal Disorders
- Autoimmune Disorders
- Dermatology
- Others
- By Cell Type
- Stem Cell Therapies
- BM, Blood, & Umbilical cord-derived Stem Cells
- Adipose-derived cells
- Others
- Non-stem Cell Therapies
- Stem Cell Therapies
- By Therapeutic Area
- Research-use
- Clinical-use
- Therapy Type Outlook
- Allogenic Therapies
- Autologous Therapies
- Regional Outlook
- U.S.
- North America
- Canada
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37509
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333